In our cohort, 25 (7.5%) patients were hypercoagulable on one or more hypercoagulable panel tests, with antithrombin III deficiency being the most common hypercoagulable condition: 12 (4%) patients in the no thrombosis group versus 5 (18%) patients in the thrombosis group (p = 0.0009). This evidence concerns the gene SERPINC1 and deep vein thrombosis.